European Association for the Study of the Liver (<scp>EASL</scp>), European Association for the Study of Diabetes (<scp>EASD</scp>) and European Association for the Study of Obesity (<scp>EASO</scp>) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes

Abstract

The application of these new algorithms for the diagnosis, and follow-up of non-alcoholic fatty liver disease would lead to an excessive number of people with Type 2 diabetes being referred to a liver clinic. We suggest that new clinical and/or biological biomarkers of steatosis and fibrosis be specifically validated in people with Type 2 diabetes.